Thase M E, Dubé S, Bowler K, Howland R H, Myers J E, Friedman E, Jarrett D B
Department of Psychiatry, University of Pittsburgh School of Medicine, PA 15213, USA.
Am J Psychiatry. 1996 Jul;153(7):886-91. doi: 10.1176/ajp.153.7.886.
Surprisingly little research supports the hypothesis that depressions characterized by objective measures of neurobiological dysregulation respond poorly to psychotherapy. Moreover, relevant studies testing this hypothesis have been compromised by low rates of neurobiological abnormality in outpatient samples. The authors therefore investigated response to cognitive behavior therapy in relation to pretreatment measures of hypothalamic-pituitary-adrenocortical (HPA) activity in hospitalized, yet unmedicated, patients.
The subjects were 29 unmedicated, hospitalized patients with major depression (DSM-III-R and Schedule for Affective Disorders and Schizophrenia/Research Diagnostic Criteria), nonpsychotic/nonbipolar subtype. After a 7- to 14-day evaluation, urinary free cortisol levels and dexamethasone suppression tests (DSTs) were obtained. Patients were treated for an average of 3 weeks with intensive individual cognitive behavior therapy. Response was assessed in relation to clinical severity of illness and pretreatment HPA parameters.
Response to inpatient cognitive behavior therapy was inversely associated with pretreatment urinary free cortisol concentrations, although not strongly correlated with DST results. Overall, 12 (92%) of 13 cortisol suppressors on the DST who had normal urinary free cortisol concentrations responded to treatment, compared with only seven (44%) of the 16 patients characterized by nonsuppression of cortisol and/or elevated urinary free cortisol excretion. The relation between response to cognitive behavior therapy and HPA activity was not explained by clinical measures of symptom severity.
Results are consistent with the hypothesis that patients with increased HPA function are less responsive to psychotherapy and, hence, might require somatic interventions. It is proposed that the negative impact of hypercortisolism on neurocognitive function mediates this relationship.
令人惊讶的是,很少有研究支持这样一种假说,即由神经生物学失调的客观指标所表征的抑郁症对心理治疗反应不佳。此外,检验这一假说的相关研究因门诊样本中神经生物学异常发生率较低而受到影响。因此,作者调查了住院但未用药患者的下丘脑-垂体-肾上腺皮质(HPA)活动的预处理指标与认知行为疗法反应之间的关系。
研究对象为29名未用药的住院重度抑郁症患者(DSM-III-R以及情感障碍和精神分裂症量表/研究诊断标准),非精神病性/非双相亚型。经过7至14天的评估后,获取尿游离皮质醇水平和地塞米松抑制试验(DST)结果。患者接受了平均3周的强化个体认知行为疗法治疗。根据疾病的临床严重程度和预处理HPA参数评估反应情况。
住院认知行为疗法的反应与预处理尿游离皮质醇浓度呈负相关,尽管与DST结果的相关性不强。总体而言,DST中13名尿游离皮质醇浓度正常的皮质醇抑制者中有12名(92%)对治疗有反应,相比之下,16名以皮质醇不抑制和/或尿游离皮质醇排泄升高为特征的患者中只有7名(44%)有反应。认知行为疗法反应与HPA活动之间的关系不能用症状严重程度的临床指标来解释。
结果与以下假说一致,即HPA功能增强的患者对心理治疗反应较差,因此可能需要躯体干预。有人提出,高皮质醇血症对神经认知功能的负面影响介导了这种关系。